Skip to main content

Table 2 Dose intensity and treatment compliance

From: Postoperative XELOX therapy for patients with curatively resected high-risk stage II and stage III rectal cancer without preoperative chemoradiation: a prospective, multicenter, open-label, single-arm phase II study

 

n = 107

Total dose, median (range), mg/m2

 Capecitabine

180,000 (1008–292,174)

 Oxaliplatin

788.1 (26.6–1079.6)

Relative dose intensity, median (range), %

 Capecitabine

83.7 (3.5–130.4)

 Oxaliplatin

82.4 (3.8–198.8)

 Course of treatment, median (range)

8 (1–8)